Filing Details

Accession Number:
0001209191-23-032707
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-05-26 19:29:02
Reporting Period:
2023-05-25
Accepted Time:
2023-05-26 19:29:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1061027 Viracta Therapeutics Inc. VIRX Pharmaceutical Preparations (2834) 943295878
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1706176 R. Daniel Chevallard C/O Viracta Therapeutics, Inc.
2533 S Coast Hwy 101, Suite 210
Cardiff CA 92007
Cfo And Coo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-05-25 6,889 $0.00 95,912 No 4 M Direct
Common Stock Disposition 2023-05-25 3,635 $1.42 92,277 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2023-05-25 6,889 $0.00 6,889 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
55,110 No 4 M Direct
Footnotes
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.
  2. The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.
  3. Represents the weighted average share price of an aggregate total of 3,635 shares sold in the price range of $1.41 to $1.42 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  4. One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.